Be part of a truly multi-stakeholder process aiming to establish sustainable and long-lasting solutions to improve patients’ access to rare disease therapies.

Views expressed by participants will go towards producing a roadmap document aiming to offer practical and implementable solutions towards the goal of accelerating the development of effective therapies and guaranteeing timely and universal access to rare disease therapies with the commitment of all players.

This roadmap will be broadly disseminated to European and national institutions ahead of the May 2019 European Parliamentary elections.

WHO WILL ATTEND?

Patient advocates
Payers, health technology assessment (HTA) bodies, and National Competent Authorities
Policy makers and regulators

Clinicians and academics
Pharmaceutical and biotech industry leaders
Consultants and Investors

WHY ATTEND?

✔ Express
the views of your stakeholder group

✔ Provide
input on practical and implementable solutions to include in the roadmap document

✔ Be part of
the cooperative solution-building process to improve patient access to rare disease therapies

✔ Learn
about actions planned ahead of the European election in May 2019

HOW TO REGISTER?

Registration will open mid-November 2018 via our website: eurordis.org

More information: www.eurordis.org | Questions: Martina Bergna at martina.bergna@eurordis.org or tel. +33 (0)1 56 53 52 66